Proffered Paper - NSCLC metastatic 1
1257O - Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
The abstract concludes: In pts with heavily pretreated NSCLC, durable responses to sotorasib were seen, with the majority of pts achieving disease control leading to a median PFS of 6.9 months. The current limited dataset suggests that neither KRAS p.G12C MAF nor PD-L1 expression level predicts response to sotorasib.
See also NEJM ORIGINAL ARTICLE
D.S. Hong and Others
1258O - Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC
The abstract concludes: Amivantamab can be combined safely with lazertinib at their respective full monotherapy doses. Encouraging preliminary activity was observed in osimertinib-relapsed disease: updated data will be presented.
Novel combinations in EGFR positive advanced NSCLC Watch now > (ecancer video)
Dr Alex Spira and Dr Joshua Sabari
Read also ESMO's Daily Reporter News:
LBA50 - ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)
The abstract concludes: Apatinib plus gefitinib as first-line therapy demonstrated superior PFS. TP53 exon 8 mutation status could serve as an efficacy predictor. Safety profiles were consistent with that of the individual drugs and acceptable.
1259O - A randomized phase II study of osimertinib with or without bevacizumab in advanced lung adenocarcinoma patients with EGFR T790M mutation (West Japan Oncology Group 8715L)
The abstract concludes: Compared with Osi, Osi+Bv failed to show prolongation of PFS in advanced lung adenocarcinoma patients with EGFR T790M mutation.
The abstract concludes: Tepotinib demonstrated durable clinical activity across subgroups in the largest study of patients with MET exon 14 skipping NSCLC prospectively enrolled by liquid or tissue biopsy. Overall ORR by IRC was 45.2% with a median DOR of11.1months, and ORR by INV was 54.1% with a median DOR of 12.7 months. Consistent ORRs were seen across subgroups,including previously treated and treatment-naïve patients. Tepotinib had a manageable safety profile,with a low number of discontinuations due to adverse events.
The abstract concludes: Tepotinib administration resulted in tumor regression in MET-driven PDX models obtained from lung cancer brain metastases • PDXs implanted orthotopically in the brain regressed upon treatment with tepotinib, supporting the activity of tepotinib in the brain • The efficacy and safety profile of tepotinib in patients with brain metastases was comparable to the overall MET exon 14 skipping population in VISION Cohort A • Activity of tepotinib in patients with brain metastases will be assessed in further detail by follow-up brain scans in the confirmatory VISION Cohort C